Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563524 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
A Phase 1 study of Psoriasis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT00563524 is a Phase 1 study of Psoriasis that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 76 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00563524, a Phase 1 study of Psoriasis, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
Conditions Studied
Interventions
- DRUG ILV-094
Study Locations (20)
Indiana
- Hudson Dermatology - Evansville
- Dawes Fretzin Clinical Research Group - Indianapolis
- Dawes Fretzin Dermatology Group - Indianapolis
Alberta
- Stratical Medical - Edmonton
- University of Alberta, Hospital Site Clinical Sciences Building - Edmonton
- The Northern Alberta Clinical Trials and Research Centre (NACTRC) - Edmonton
California
- David Stoll, MD - Beverly Hills
- Dermatology Research - Santa Monica
Florida
- Miami Research Associates - South Miami
- MRA Clinical Research - South Miami
New York
- New York University Medical Center - New York
- Mount Sinai School of Medicine - New York
Ontario
- Bio Pharma Services Inc - Toronto
- K. Papp Clinical Research - Waterloo
Michigan
- Hamzavi Dermatology - Fort Gratiot
Missouri
- Central Dermatology - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2007-12-20 |
| Est. Completion | 2010-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563524
The ClinicalTrials.gov registry entry for NCT00563524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ILV-094 is the first listed.
NCT00563524 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Indiana, Alberta, California.
Frequently Asked Questions
What is clinical trial NCT00563524 about?
NCT00563524 is a clinical study titled "Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis". The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
What is the current status of trial NCT00563524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2007-12-20. Estimated completion is 2010-06-14.
What conditions does trial NCT00563524 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00563524?
The interventions under investigation include: ILV-094 (DRUG).
Who is sponsoring clinical trial NCT00563524?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00563524 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.